Lantheus Holdings, Inc. (LNTH)
USD 108.74
(2.66%)
USD 108.74
(2.66%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 709.54 Million USD | 21.98% |
| 2022 | 581.7 Million USD | 209.92% |
| 2021 | 187.69 Million USD | 35.26% |
| 2020 | 138.76 Million USD | -20.62% |
| 2019 | 174.81 Million USD | -0.04% |
| 2018 | 174.88 Million USD | 7.86% |
| 2017 | 162.13 Million USD | 17.68% |
| 2016 | 137.78 Million USD | 1.67% |
| 2015 | 135.52 Million USD | 7.97% |
| 2014 | 125.51 Million USD | 62.25% |
| 2013 | 77.36 Million USD | 2.88% |
| 2012 | 75.19 Million USD | -21.02% |
| 2011 | 95.21 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 255.77 Million USD | 1.59% |
| 2024 Q1 | 251.77 Million USD | 9.53% |
| 2023 Q2 | 202.64 Million USD | 162.92% |
| 2023 Q1 | 77.07 Million USD | -53.89% |
| 2023 FY | 709.54 Million USD | 21.98% |
| 2023 Q4 | 229.86 Million USD | 14.96% |
| 2023 Q3 | 199.95 Million USD | -1.33% |
| 2022 Q4 | 167.17 Million USD | 13.39% |
| 2022 Q1 | 129.07 Million USD | 122.89% |
| 2022 Q2 | 138.02 Million USD | 6.94% |
| 2022 Q3 | 147.43 Million USD | 6.81% |
| 2022 FY | 581.7 Million USD | 209.92% |
| 2021 FY | 187.69 Million USD | 35.26% |
| 2021 Q1 | 41.03 Million USD | 6.16% |
| 2021 Q3 | 42.66 Million USD | -7.42% |
| 2021 Q4 | 57.9 Million USD | 35.71% |
| 2021 Q2 | 46.08 Million USD | 12.33% |
| 2020 Q4 | 38.65 Million USD | 6.59% |
| 2020 Q3 | 36.26 Million USD | 40.28% |
| 2020 FY | 138.76 Million USD | -20.62% |
| 2020 Q2 | 25.84 Million USD | -31.98% |
| 2020 Q1 | 38 Million USD | -14.73% |
| 2019 Q4 | 44.56 Million USD | 7.16% |
| 2019 Q1 | 44.08 Million USD | 0.55% |
| 2019 Q2 | 44.57 Million USD | 1.11% |
| 2019 FY | 174.81 Million USD | -0.04% |
| 2019 Q3 | 41.58 Million USD | -6.69% |
| 2018 Q2 | 43.84 Million USD | 3.63% |
| 2018 FY | 174.88 Million USD | 7.86% |
| 2018 Q1 | 42.3 Million USD | 11.64% |
| 2018 Q4 | 43.84 Million USD | -2.32% |
| 2018 Q3 | 44.88 Million USD | 2.37% |
| 2017 FY | 162.13 Million USD | 17.68% |
| 2017 Q3 | 38.52 Million USD | -16.15% |
| 2017 Q2 | 45.94 Million USD | 15.56% |
| 2017 Q1 | 39.76 Million USD | 14.76% |
| 2017 Q4 | 37.89 Million USD | -1.63% |
| 2016 Q2 | 35.75 Million USD | 6.08% |
| 2016 FY | 137.78 Million USD | 1.67% |
| 2016 Q4 | 34.64 Million USD | 2.87% |
| 2016 Q1 | 33.7 Million USD | 0.96% |
| 2016 Q3 | 33.68 Million USD | -5.79% |
| 2015 Q2 | 32.66 Million USD | -8.67% |
| 2015 Q1 | 35.76 Million USD | 9.18% |
| 2015 Q3 | 33.7 Million USD | 3.18% |
| 2015 FY | 135.52 Million USD | 7.97% |
| 2015 Q4 | 33.38 Million USD | -0.96% |
| 2014 Q2 | 31.05 Million USD | 3.32% |
| 2014 FY | 125.51 Million USD | 62.25% |
| 2014 Q4 | 32.76 Million USD | 3.55% |
| 2014 Q3 | 31.63 Million USD | 1.86% |
| 2014 Q1 | 30.06 Million USD | 204.23% |
| 2013 FY | 77.36 Million USD | 2.88% |
| 2013 Q1 | 22.81 Million USD | -16.97% |
| 2013 Q2 | 20.94 Million USD | -8.18% |
| 2013 Q3 | 23.72 Million USD | 13.24% |
| 2013 Q4 | 9.88 Million USD | -58.34% |
| 2012 FY | 75.19 Million USD | -21.02% |
| 2012 Q4 | 27.47 Million USD | 0.0% |
| 2011 FY | 95.21 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 305.3 Million USD | -132.406% |
| Aquestive Therapeutics, Inc. | 29.75 Million USD | -2284.858% |
| Collegium Pharmaceutical, Inc. | 326.16 Million USD | -117.538% |
| Cosmos Health Inc. | 4.34 Million USD | -16212.95% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 29539.468% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | -871.085% |
| Cronos Group Inc. | 6.99 Million USD | -10049.529% |
| Incannex Healthcare Limited | 12 Thousand USD | -5912758.333% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 234272.607% |
| Lifecore Biomedical, Inc. | 41.85 Million USD | -1595.443% |
| Regencell Bioscience Holdings Limited | -745.58 Thousand USD | 95265.561% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -8408.556% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -8408.556% |
| SCYNEXIS, Inc. | 124.51 Million USD | -469.836% |
| Safety Shot Inc | -74.45 Thousand USD | 953056.74% |
| Theratechnologies Inc. | 62.12 Million USD | -1042.048% |
| Alpha Teknova, Inc. | 10.29 Million USD | -6791.443% |
| Universe Pharmaceuticals INC | 10.07 Million USD | -6940.598% |
| Pacira BioSciences, Inc. | 490.3 Million USD | -44.713% |
| Sonoma Pharmaceuticals, Inc. | 4.74 Million USD | -14853.488% |
| Dynavax Technologies Corporation | 182.11 Million USD | -289.608% |
| Ironwood Pharmaceuticals, Inc. | 441.16 Million USD | -60.836% |
| Radius Health, Inc. | 307.71 Million USD | -130.587% |
| China SXT Pharmaceuticals, Inc. | 553.97 Thousand USD | -127983.058% |
| Alvotech | -69.42 Million USD | 1122.072% |
| Intra-Cellular Therapies, Inc. | 430.62 Million USD | -64.771% |
| SIGA Technologies, Inc. | 122.09 Million USD | -481.154% |
| Shineco, Inc. | 882.16 Thousand USD | -80331.732% |
| Silver Spike Investment Corp. | 8.1 Million USD | -8656.98% |
| Journey Medical Corporation | 52.52 Million USD | -1250.97% |
| Petros Pharmaceuticals, Inc. | 4.19 Million USD | -16829.481% |
| Embecta Corp. | 749.9 Million USD | 5.382% |
| Harrow Health, Inc. | 90.55 Million USD | -683.567% |
| Procaps Group, S.A. | 239.56 Million USD | -196.175% |
| Biofrontera Inc. | 16.62 Million USD | -4167.414% |
| DURECT Corporation | 6.83 Million USD | -10287.103% |
| PainReform Ltd. | -15 Thousand USD | 4730386.667% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | -35.476% |
| OptiNose, Inc. | 62.35 Million USD | -1037.927% |
| RedHill Biopharma Ltd. | 3.05 Million USD | -23131.919% |
| Organogenesis Holdings Inc. | 309.79 Million USD | -129.04% |
| Cumberland Pharmaceuticals Inc. | 33.48 Million USD | -2018.931% |
| ProPhase Labs, Inc. | 16.23 Million USD | -4269.376% |
| Phibro Animal Health Corporation | 312.48 Million USD | -127.063% |
| Procaps Group S.A. | 239.56 Million USD | -196.175% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -54396.39% |
| Viatris Inc. | 6.43 Billion USD | 88.98% |
| Rockwell Medical, Inc. | 8.7 Million USD | -8051.919% |
| Aytu BioPharma, Inc. | 54.58 Million USD | -1199.863% |
| Tilray Brands, Inc. | 223.35 Million USD | -217.681% |
| PetIQ, Inc. | 252.74 Million USD | -180.74% |
| Talphera, Inc. | -4.89 Million USD | 14595.26% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 61.592% |
| Alimera Sciences, Inc. | 61.17 Million USD | -1059.953% |
| Assertio Holdings, Inc. | 125.04 Million USD | -467.412% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6811.00 USD | 10417703.876% |
| Avadel Pharmaceuticals plc | 27.11 Million USD | -2516.598% |
| Hempacco Co., Inc. | -1.21 Million USD | 58458.59% |
| Alvotech | -69.42 Million USD | 1122.072% |
| Kamada Ltd. | 52.59 Million USD | -1249.127% |
| Currenc Group, Inc. | 17.35 Million USD | -3988.099% |
| Indivior PLC | 907 Million USD | 21.77% |
| Evoke Pharma, Inc. | 4.97 Million USD | -14151.426% |
| Flora Growth Corp. | 17.73 Million USD | -3900.13% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 29539.468% |
| Evolus, Inc. | 140.52 Million USD | -404.919% |
| HUTCHMED (China) Limited | 453.55 Million USD | -56.441% |
| Amphastar Pharmaceuticals, Inc. | 343.96 Million USD | -106.282% |
| Akanda Corp. | 111.44 Thousand USD | -636552.639% |